Royal Bank of Canada
KTTA icon

Royal Bank of Canada’s Pasithea Therapeutics KTTA Stock Holding History

Royal Bank of Canada’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed – – 7423
2025
Q4 		$0 Hold
250
– – ﹤0.01% 7400
2025
Q3 		$0 Hold
250
– – ﹤0.01% 7327
2025
Q2 		$0 Hold
250
– – ﹤0.01% 7191
2025
Q1 		$0 Hold
250
– – ﹤0.01% 7039
2024
Q4 		$1K Hold
250
– – ﹤0.01% 6790
2024
Q3 		$1K Hold
250
– – ﹤0.01% 6719
2024
Q2 		$1K Hold
250
– – ﹤0.01% 6840
2024
Q1 		$2K Hold
250
– – ﹤0.01% 6682
2023
Q4 		$2K Hold
250
– – ﹤0.01% 6813
2023
Q3 		$2K Hold
250
– – ﹤0.01% 6800
2023
Q2 		$2K Hold
250
– – ﹤0.01% 6883
2023
Q1 		$2K Hold
250
– – ﹤0.01% 6778
2022
Q4 		$3K Buy
+250
New +$5K ﹤0.01% 6862

Other funds holding KTTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada's KTTA Position: Q1 2026 in Review

Royal Bank of Canada sold out of Pasithea Therapeutics (KTTA) in Q1 2026, closing a stake of 250 shares.

Royal Bank of Canada first reported a position in KTTA in Q4 2022 and held it in 13 quarters. The position peaked at $3K in Q4 2022. 21 funds tracked by Wall St. Rank hold KTTA as of Q1 2026.

  • Royal Bank of Canada reported no remaining Pasithea Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Royal Bank of Canada sold 250 Pasithea Therapeutics shares in Q1 2026.
  • Royal Bank of Canada first reported a position in Pasithea Therapeutics in Q4 2022 and held it in 13 quarters.
  • Royal Bank of Canada's Pasithea Therapeutics position peaked at $3K in Q4 2022.
  • 21 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.